Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBENDAZOLE vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Cystic hydatid disease (Echinococcus granulosus),Neurocysticercosis (Taenia solium),Giardiasis (off-label),Cutaneous larva migrans (off-label),Trichuriasis (off-label),Ascariasis (off-label),Hookworm infections (off-label)
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
250-350 mg orally 3 times daily and at bedtime
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Primarily hepatic via microsomal enzymes; undergoes oxidation to albendazole sulfoxide (active metabolite) by CYP3A4 and flavin-containing monooxygenases (FMO). Further metabolized to albendazole sulfone (inactive) and other oxidative metabolites.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
70% bound to plasma proteins, primarily albumin.
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
0.2–0.6 L/kg, indicating distribution into tissues; concentrates in liver, bile, and cerebrospinal fluid.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral bioavailability is low (~5%) due to extensive first-pass metabolism; co-administration with a high-fat meal increases bioavailability up to 4–5-fold.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <15 m L/min), use with caution; consider dose reduction or extended intervals. No specific GFR-based guidelines available.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function. No specific dose adjustment guidelines available.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
For children >2 years: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for most indications. For neurocysticercosis: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 8-30 days. For hydatid disease: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 28-day cycles with 14-day drug-free intervals. For children <2 years: safety and efficacy not established.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
No specific dose adjustment recommended; use with caution due to potential age-related hepatic or renal impairment. Monitor liver function and blood counts regularly.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
Albendazole may cause fetal harm when administered to pregnant women. It is contraindicated in pregnancy and should not be used in women who are or may become pregnant. Women of childbearing potential should have a negative pregnancy test before starting treatment and should use effective contraception during therapy and for one month after completion.
None
Bone marrow suppression: Monitor CBC at start and periodically; risk of pancytopenia, particularly in patients with hepatic disease or receiving high doses.,Hepatotoxicity: Monitor liver function tests due to risk of elevated transaminases and rare hepatic failure.,Risk of neurocysticercosis exacerbation: May cause increased intracranial pressure or seizures; treat with corticosteroids and anticonvulsants as needed.,Retinal damage: In ocular neurocysticercosis, evaluate for retinal lesions before therapy due to risk of retinal damage from inflammation.,Renal impairment: Use with caution; dose adjustment may be necessary.,Lactation: Excreted in breast milk; caution in nursing mothers.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Pregnancy (absolute),Known hypersensitivity to albendazole or any of its components,Patients with pre-existing bone marrow suppression (relative)
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Take with a high-fat meal (≥40 g fat) to significantly increase oral bioavailability. Avoid grapefruit juice as it may affect drug metabolism. No specific dietary restrictions otherwise.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal harm; avoid use unless benefit outweighs risk.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Excreted in breast milk; M/P ratio not established. Use with caution, especially in neonates due to risk of bone marrow suppression.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
No specific dose adjustment recommended in pregnancy; pharmacokinetic changes not well studied. Use lowest effective dose and shortest duration possible.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
Albendazole is a broad-spectrum anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin. It is highly effective against Echinococcus granulosus cysts but requires prolonged therapy (e.g., 28-day cycles). Monitor liver function tests (LFTs) at baseline and every 2 weeks due to risk of hepatotoxicity. For neurocysticercosis, co-administer corticosteroids to reduce inflammatory reaction from cyst degeneration. Albendazole is pregnancy category C; avoid in first trimester and in women planning pregnancy within 1 month of therapy. Absorption is enhanced by a fatty meal; administer with a high-fat meal to increase bioavailability up to 5-fold.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Take this medication with a fatty meal (e.g., eggs, avocado, nuts) to improve absorption.,Do not crush or chew the tablets; swallow them whole with water.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea, or abdominal pain.,Avoid pregnancy during treatment and for at least 1 month after the last dose; use reliable contraception.,You may experience dizziness or blurred vision; avoid driving or operating machinery until you know how the drug affects you.,If you are breastfeeding, discuss with your doctor before taking this medication.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
"Albendazole inhibits the CYP3A4-mediated metabolism of clemastine, leading to increased plasma concentrations of clemastine. This can potentiate the anticholinergic and sedative effects of clemastine, including dry mouth, urinary retention, constipation, and drowsiness. Patients may experience heightened central nervous system depression, especially with concurrent use of other CNS depressants."
"Ranolazine, a piperazine derivative antianginal agent, is a moderate CYP3A4 inhibitor. Albendazole is primarily metabolized by CYP3A4 to its active metabolite, albendazole sulfoxide. Coadministration increases albendazole systemic exposure by approximately 50%, potentially enhancing both therapeutic efficacy and dose-dependent toxicities, including hepatotoxicity and bone marrow suppression."
"Albendazole inhibits CYP3A4, the enzyme primarily responsible for the metabolism of lovastatin. This inhibition reduces lovastatin clearance, leading to elevated plasma concentrations and increased risk of statin-related adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Patients receiving this combination should be monitored closely for signs of muscle pain or weakness and liver enzyme abnormalities."
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBENDAZOLE vs CARISOPRODOL, answered by our medical review team.
ALBENDAZOLE is a Anthelmintic that works by Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBENDAZOLE and CARISOPRODOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBENDAZOLE is: 400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBENDAZOLE and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBENDAZOLE is classified as Category D/X. FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.